Roche is acquiring Vienna, Austria-based mySugr, its long-standing partner in fight "against" diabetes. As part of the deal, mySugr — which is one of the leading mobile diabetes platforms in the market — will become an integral part of Roche's new patient-centered digital health services platform in diabetes care.
"We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life," Roland Diggelmann, CEO of Roche Diagnostics, said in a statement. "Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes."
mySugr will remain a separate legal entity with an open platform for all diabetes devices and services. Users will still be able to automatically upload blood glucose data from their preferred device into the mySugr logbook app as well as share their data with healthcare professionals and caregivers.
"We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones," said Frank Westermann, CEO and Co-Founder of mySugr. "The mySugr team has filled a gap for over a million loyal users so far, and with Roche's diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life."
Terms of the deal, including how much money Roche paid for mySugr, were not disclosed. For what it matters, mySugr has raised $6.63 million to date, with Roche Ventures acting as one its investors.